Biofrontera, Inc. Recognized for Rapid Sales Growth, Innovative Therapies and Marketing Excellence
June 09 2022 - 8:44AM
Biofrontera
Inc. (Nasdaq: BFRI),
a biopharmaceutical company specializing in the commercialization
of dermatological products, announced today that the Company has
been recognized for its contributions to the life sciences industry
and for its newest Ameluz® marketing campaign.
Biofrontera was named by CIOCoverage Magazine as
one of the 10 fastest-growing life sciences companies to watch in
20221. The publication recognized Biofrontera’s commitment to its
industry and wrote, “as one of the most forward-thinking companies,
Biofrontera Inc. brings unparalleled therapies and service to
patients and healthcare providers in the dermatology community by
focusing on innovative therapy options that enable dermatology
healthcare professionals to help improve the lives of their
patients2.”
Separately, Biofrontera’s new Ameluz® marketing
campaign with a creative call to action emphasizing the threat of
actinic keratoses (AK), titled “Danger Lurks Below the Surface” and
featuring images of sharks, earned a Gold 2022 Award of Excellence3
from The Communicator Awards, a leading international
industry-agnostic awards program recognizing excellence in
communication, championing effective and meaningful work. This
campaign, which was developed in collaboration with the
healthcare-focused branding agency Elevate Healthcare Marketing,
aims to create awareness of the danger associated with visible and
invisible AKs. It also positions Ameluz® plus BF-RhodoLED®
(Ameluz®-PDT) as the only photodynamic therapy with an approval for
field treatment that enables healthcare professionals to protect
patients against the risks posed by fields of premalignant AKs.
“I am proud of my colleagues and our
collaborators who help us to deliver such a high standard of
patient satisfaction and innovation, and congratulate them on
Biofrontera being profiled by these two specialty media
publications. CIOCoverage Magazine recognized Biofrontera for
‘exhibiting excellence in transforming life sciences business,’ and
we aim to keep delivering that excellence throughout 2022 and
beyond. Our latest Ameluz® marketing campaign is resonating
extremely well as we are hearing from dermatologists of growing
awareness among their patients of precancerous skin lesions and the
danger they represent,” stated Erica Monaco, Chief Executive
Officer of Biofrontera Inc.
_________________110 Fastest Growing Life
Sciences Companies to Watch
2022 https://www.ciocoverage.com/10-fastest-growing-life-sciences-companies-to-watch-in-2022/
2Biofrontera – Dermatology company with products
for the treatment of actinic keratosis with photodynamic
therapy https://www.ciocoverage.com/biofrontera-dermatology-company-with-products-for-the-treatment-of-actinic-keratosis-with-photodynamic-therapy/
3Ameluz – Danger Lurks
campaign https://awards.healthcare/ameluz/
About Actinic
Keratosis
Actinic keratosis (AK) is a superficial,
potentially pre-cancerous skin lesion caused by chronic sun
exposure that may, if left untreated, develop into life-threatening
skin cancer called squamous cell carcinoma. AKs typically appear on
sun-exposed areas such as the face, bald scalp, arms or the back of
the hands. According to the Skin Cancer Foundation, in the U.S. AK
affected approximately 58 million people in 2020 and an estimated
12.7 million AK treatments were performed. The most common
treatment for AK is cryotherapy, with approximately 86% of the
market. Topical drugs for the treatment of AK had a market share of
about 12%, followed by photodynamic therapy (PDT) treatments with
about a 2% share.
About
Ameluz®
Ameluz® (aminolevulinic acid hydrochloride gel,
10%), Biofrontera’s flagship product, is FDA-approved for use in
combination with the BF-RhodoLED® lamp for photodynamic therapy
(PDT) for the lesion-directed and field-directed treatment of
actinic keratosis (AK) of mild-to-moderate severity on the face and
scalp. Biofrontera’s commercial focus is to improve the market
positioning of Ameluz® to become the leading PDT drug for the
treatment of AK, especially in patients with more than 15 lesions,
and positioning Ameluz® as the number one treatment choice for
patients with extended skin areas affected by AK. Ameluz® and
Biofrontera’s RhodoLED® lamp series are being further developed
through ongoing clinical studies by Biofrontera’s license and
supply partner.
About Biofrontera Inc.
Biofrontera Inc. is a U.S.-based
biopharmaceutical company commercializing a portfolio of
pharmaceutical products for the treatment of dermatological
conditions with a focus on PDT and topical antibiotics. The
Company’s licensed products are used for the treatment of actinic
keratoses, which are pre-cancerous skin lesions, as well as
impetigo, a bacterial skin infection. For more information,
visit https://www.biofrontera-us.com.
Forward-Looking Statements
Certain statements in this press release may
constitute "forward-looking statements" within the meaning of the
United States Private Securities Litigation Reform Act of 1995, as
amended to date. These statements include, but are not limited to,
statements relating to the Company’s business and marketing
strategy, future operations and business, potential to expand the
label of Ameluz®, market presence and position of Ameluz® and
ongoing clinical trials conducted by our licensing partners and the
future impact of such trials on the market for Ameluz®. We have
based these forward-looking statements on our current expectations
and projections about future events, nevertheless, actual results
or events could differ materially from the plans, intentions and
expectations disclosed in, or implied by, the forward-looking
statements we make. These risks and uncertainties, many of which
are beyond our control, including, but not limited to, the impact
of extraordinary external events, such as the current COVID-19
pandemic; any changes in the Company’s relationship with its
licensors; the ability of the Company’s licensors to fulfill their
obligations to the Company in a timely manner; the Company’s
ability to achieve and sustain profitability; whether the current
global disruptions in supply chains will impact the Company’s
ability to obtain and distribute its licensed products; changes in
the practices of healthcare providers, including any changes to the
coverage, reimbursement and pricing for procedures using the
Company’s licensed products; the uncertainties inherent in the
initiation and conduct of clinical trials; availability and timing
of data from clinical trials; whether results of earlier clinical
trials or trials of Ameluz® in combination with BF-RhodoLED® in
different disease indications or product applications will be
indicative of the results of ongoing or future trials;
uncertainties associated with regulatory review of clinical trials
and applications for marketing approvals; whether the market
opportunity for Ameluz® in combination with BF-RhodoLED® is
consistent with the Company’s expectations; the Company’s ability
to complete the transition to a public company; the Company’s
ability to retain and hire key personnel; the sufficiency of cash
resources and need for additional financing and other factors that
may be disclosed in the Company’s filings with the SEC, which can
be obtained on the SEC website at www.sec.gov. Readers are
cautioned not to place undue reliance on the forward-looking
statements, which speak only as of the date on which they are made
and reflect management's current estimates, projections,
expectations and beliefs. The Company does not plan to update any
such forward-looking statements and expressly disclaims any duty to
update the information contained in this press release except as
required by law.
Contacts
Biofrontera Inc.Anke zur
Mühlen+1 781 486 1539us-ir@biofrontera.com
LHA Investor RelationsTirth T.
Patel+1 212 201 6614tpatel@lhai.com
# # #
Biofrontera (NASDAQ:BFRIW)
Historical Stock Chart
From Aug 2024 to Sep 2024
Biofrontera (NASDAQ:BFRIW)
Historical Stock Chart
From Sep 2023 to Sep 2024